报告题目: Nanoparticle drug delivery systems: the promise, challenges, and opportunities

报告人  : Yoon Yeo 教授，Purdue University

报告时间: 2018年12月27日10:00-11:30

报告地点:生科院二楼大会议室

邀请人  :李子福 教授

专家简介

Yoon Yeo is a Professor and Associate Department Head of Industrial and Physical Pharmacy at the College of Pharmacy with a join appointment in Biomedical Engineering and a Showalter Faculty Scholar at Purdue University. She received her B.S. in Pharmacy and M.S. in Microbial Chemistry at Seoul National University in Korea, and Ph.D. in Pharmaceutics at Purdue, West Lafayette, USA. She obtained post-doctoral training at Massachusetts Institute of Technology and returned to Purdue to join the faculty in 2007. Her research focuses on nanoparticle surface engineering for drug delivery to solid tumors, intracellular delivery of peptide antibiotics, anion-resistant non-viral gene vectors, and functional biomaterials for immunomodulation. She has authored 95 peer-reviewed papers and 9 book chapters, and received the NSF CAREER award (2011), New Investigator Awards from the American Association of Pharmaceutical Scientists (2009), and American Association of Colleges of Pharmacy (2008). Her research program is funded by the NIH and NSF.

摘要：

Nanoparticles (NPs) are widely explored as drug carriers in order to alter the pharmacokinetics and biodistribution of their drug payloads, thereby enhancing their efficacy and reduce side effects. For example, NPs are excellent tools for the treatment of intracellular bacterial infection due to the ability to enter cells that the commonly used antibiotics cannot easily access. With optimal size and composition, NPs can bring a large amount of antibiotics into the infected cells with little effects on normal tissues. Our lab has developed NP system that can deliver vancomycin to methicillin-resistant staphylococcus aureus (MRSA)-infected macrophages and effectively reduce the bacterial burden in the cells. NPs have also been explored for targeted delivery of chemotherapeutic drugs to tumors based on hyperpermeability of tumor vasculature that allows selective access of NPs. This promise has recently been challenged as leading NP products did not meet expectations in clinical trials. We recognize several obstacles that current NP technologies have not properly overcome, such as poor circulation stability, limited drug loading capacity of NPs, and immunosuppressive microenvironment of tumors. Our lab has developed new strategies to enhance the delivery of NPs to tumors. Such efforts include the development of (i) quinic acid-coated polymeric nanoparticles, which interact with peritumoral endothelium for efficient extravasation in tumors, (ii) albumin-coated nanocrystals, which exploit the albumin-transport mechanism to reach tumors, and (iii) siRNA-carrying NPs that modulate the tumor microenvironment. In this talk, I will introduce our new NP drug delivery systems and discuss remaining challenges and opportunities.

    欢迎学院师生积极参加！